Respiratory syncytial virus prevention within reach: the vaccine and monoclonal antibody landscape

Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. 33 respiratory syncytial virus prevent...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:The Lancet infectious diseases Ročník 23; číslo 1; s. e2 - e21
Hlavní autori: Mazur, Natalie I, Terstappen, Jonne, Baral, Ranju, Bardají, Azucena, Beutels, Philippe, Buchholz, Ursula J, Cohen, Cheryl, Crowe, James E, Cutland, Clare L, Eckert, Linda, Feikin, Daniel, Fitzpatrick, Tiffany, Fong, Youyi, Graham, Barney S, Heikkinen, Terho, Higgins, Deborah, Hirve, Siddhivinayak, Klugman, Keith P, Kragten-Tabatabaie, Leyla, Lemey, Philippe, Libster, Romina, Löwensteyn, Yvette, Mejias, Asuncion, Munoz, Flor M, Munywoki, Patrick K, Mwananyanda, Lawrence, Nair, Harish, Nunes, Marta C, Ramilo, Octavio, Richmond, Peter, Ruckwardt, Tracy J, Sande, Charles, Srikantiah, Padmini, Thacker, Naveen, Waldstein, Kody A, Weinberger, Dan, Wildenbeest, Joanne, Wiseman, Dexter, Zar, Heather J, Zambon, Maria, Bont, Louis
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States Elsevier Ltd 01.01.2023
Elsevier Limited
Predmet:
Adults
Aged
Antibodies, Monoclonal - therapeutic use
Antibodies, Viral
Antigens
Clinical trials
Data collection
Epitopes
Female
Hospitalization
Humans
Immunization
Immunoprophylaxis
Infant
Infant mortality
Infants
Infections
Infectious diseases
Monoclonal antibodies
Morbidity
Mortality
Nucleic acids
Older people
Pediatrics
Pregnancy
Prevention
Respiratory diseases
Respiratory syncytial virus
Respiratory Syncytial Virus Infections - prevention & control
Respiratory Syncytial Virus Vaccines
Respiratory Syncytial Virus, Human
Vaccines
Viruses
ISSN:1473-3099, 1474-4457, 1474-4457
On-line prístup:Získať plný text
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Popis
Shrnutí:Respiratory syncytial virus is the second most common cause of infant mortality and a major cause of morbidity and mortality in older adults (aged >60 years). Efforts to develop a respiratory syncytial virus vaccine or immunoprophylaxis remain highly active. 33 respiratory syncytial virus prevention candidates are in clinical development using six different approaches: recombinant vector, subunit, particle-based, live attenuated, chimeric, and nucleic acid vaccines; and monoclonal antibodies. Nine candidates are in phase 3 clinical trials. Understanding the epitopes targeted by highly neutralising antibodies has resulted in a shift from empirical to rational and structure-based vaccine and monoclonal antibody design. An extended half-life monoclonal antibody for all infants is likely to be within 1 year of regulatory approval (from August, 2022) for high-income countries. Live-attenuated vaccines are in development for older infants (aged >6 months). Subunit vaccines are in late-stage trials for pregnant women to protect infants, whereas vector, subunit, and nucleic acid approaches are being developed for older adults. Urgent next steps include ensuring access and affordability of a respiratory syncytial virus vaccine globally. This review gives an overview of respiratory syncytial virus vaccines and monoclonal antibodies in clinical development highlighting different target populations, antigens, and trial results.
Bibliografia:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
LB and NIM were involved in the design and plan for this Review. NIM, JT, and YL were involved in the data collection, data extraction, and quality assessment and contributed to the writing of the manuscript, in collaboration with all co-authors. JT created the figures for the manuscript with Biorender.com. The manuscript was written in collaboration with the ReSViNET Foundation.
Contributions
ISSN:1473-3099
1474-4457
1474-4457
DOI:10.1016/S1473-3099(22)00291-2